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Glutamatergic and dopaminergic function and the relationship
to outcome in people at clinical high risk of psychosis: a multi-
modal PET-magnetic resonance brain imaging study
Oliver D. Howes1,2,3, Ilaria Bonoldi1,3, Robert A. McCutcheon 1,2, Matilda Azis1, Mathilde Antoniades1, Matthijs Bossong1,4,
Gemma Modinos 1, Jesus Perez5,6, James M. Stone 1, Barbara Santangelo1, Mattia Veronese 1, Anthony Grace7, Paul Allen8 and
Philip K. McGuire1
Preclinical models of psychosis propose that hippocampal glutamatergic neuron hyperactivity drives increased striatal
dopaminergic activity, which underlies the development of psychotic symptoms. The aim of this study was to examine the
relationship between hippocampal glutamate and subcortical dopaminergic function in people at clinical high risk for psychosis,
and to assess the association with the development of psychotic symptoms. 1H-MRS was used to measure hippocampal glutamate
concentrations, and 18F-DOPA PET was used to measure dopamine synthesis capacity in 70 subjects (51 people at clinical high risk
for psychosis and 19 healthy controls). Clinical assessments were undertaken at baseline and follow-up (median 15 months). Striatal
dopamine synthesis capacity predicted the worsening of psychotic symptoms at follow-up (r= 0.35; p < 0.05), but not transition to
a psychotic disorder (p= 0.22), and was not significantly related to hippocampal glutamate concentration (p= 0.13). There were no
differences in either glutamate (p= 0.5) or dopamine (p= 0.5) measures in the total patient group relative to controls. Striatal
dopamine synthesis capacity at presentation predicts the subsequent worsening of sub-clinical total and psychotic symptoms,
consistent with a role for dopamine in the development of psychotic symptoms, but is not strongly linked to hippocampal
glutamate concentrations.
Neuropsychopharmacology (2019) 0:1–8; https://doi.org/10.1038/s41386-019-0541-2
INTRODUCTION
Psychotic disorders are typically preceded by a prodromal period
of 1–5 years, characterised by worsening sub-clinical psychotic
symptoms and a decline in overall functioning [1]. Operationalised
criteria have been developed on the basis of symptoms, functional
decline and family history of psychosis to identify people who may
be in the prodrome and are at high risk of developing psychosis in
the next few years [2]. People meeting these operationalised
criteria are referred to as being at clinical high risk of psychosis.
Psychotic disorders are associated with considerable burden once
they have developed, and current treatments are limited by poor
tolerability and effectiveness in many patients [3]. There is thus
considerable interest in understanding the pathophysiology
underlying the development of psychotic symptoms to help
develop new treatments [4].
The dopamine and glutamate hypotheses are two leading
theories for the pathophysiology of psychosis [3]. Although
initially developed separately, the hypotheses have been inte-
grated to propose that glutamate dysregulation in cortical regions,
including the hippocampus, leads to striatal dopamine
dysfunction, which, in turn, underlies the development of
psychotic symptoms [3, 5–9]. Supporting this, preclinical evidence
indicates that hippocampal hyperactivity leads to mesostriatal
dopamine dysfunction [10–12], and implicates glutamatergic
neuron dysregulation in the hippocampus in this process [13].
Moreover, a number of clinical studies have shown altered
hippocampal structure, function and perfusion in psychotic
disorders, and people at risk of psychosis [13–20]. However, to
our knowledge, only one study has investigated the relationship
between hippocampal glutamatergic measures and striatal
dopamine function in people at high risk for psychosis [21]. This
study found levels of glutamate, in the hippocampus, were
inversely related to striatal dopamine synthesis capacity in people
at clinical risk of psychosis, particularly in the subgroup who went
on to develop a psychotic disorder. This suggests the hypothesis
that dysfunction in hippocampal glutamatergic drive dysregulates
striatal dopaminergic function. As the number of subjects in the
one in vivo study in patients to date was relatively modest (n=
14), the first aim of this study was to test the hypothesis that
striatal dopamine synthesis capacity and hippocampal glutamate
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measures are related in an independent and larger sample of
clinical high-risk subjects.
In vivo imaging studies of dopaminergic function show that
dopamine synthesis and release capacity are elevated in patients
with psychosis [22, 23], and some [24, 25], but not all [26, 27],
studies have found this to be associated with the severity of
psychotic symptoms. Striatal dopamine-release capacity has also
been associated with the induction of psychotic symptoms by
amphetamine [27]. Elevated dopamine synthesis and release
capacity have also been reported in people at clinical high risk of
psychosis [28–30], but not in other groups experiencing sub-
threshold psychotic symptoms who do not meet criteria for a
psychotic disorder [31]. Raised dopamine synthesis capacity has
also been shown to be specific to those individuals who
associated with an increased risk of transition to psychosis
[32, 33]. Taken together, this evidence suggests that dopaminer-
gic dysfunction may underlie the development of psychotic
symptoms. However, it is not known if dopamine synthesis
capacity predicts the worsening of sub-clinical psychotic symp-
toms in people at risk of psychosis. Therefore, the second aim of
our study was to test the hypothesis that increased striatal
dopamine synthesis capacity would predict an increase in the
severity of psychotic symptoms, as well as the onset of a
psychotic disorder.
METHODS
Study design
The study comprised a case–control comparison of patients with
healthy controls with a longitudinal, naturalistic clinical follow-up
of patients to determine the relationship between baseline
imaging measures and clinical outcome. All volunteers received
clinical and imaging measures. In addition, the patients received
follow-up to determine clinical outcome as described below.
Ethical permission was given by the local research ethics
committee. All participants provided written informed consent
to participate.
Participants
Patients were recruited from services for people at clinical high
risk of psychosis in South England. Inclusion criteria were (1) met
operationalized criteria for being at clinical high risk of psychosis
based on a standardised, semi-structured clinical assessment as
described by Yung et al. [34]; (2) no history of current or past
psychotic disorder assessed using the structured clinical interview
for diagnosis [35] and (3) antipsychotic naive or antipsychotic-free
for at least 6 weeks.
Healthy controls were recruited from the same geographical
area via adverts in the local media and met the following inclusion
criteria: (1) no history of current or past mental disorder assessed
using the structured clinical interview for diagnosis [35]; (2) no
criteria for being at clinical high risk of psychosis as described by
Yung et al. [34] (3) antipsychotic naive or antipsychotic-free.
Exclusion criteria for all subjects were any of (1) a history of
significant head trauma, (2) dependence on illicit substances, (3)
medical co-morbidity (other than minor, self-limiting illnesses) and
(4) contraindications to scanning (such as pregnancy).
Clinical measures
At baseline, all subjects were assessed using the Global Assess-
ment of Function (GAF [36]) to measure social and occupational
function, and the National Adult Reading Test (NART) to estimate
premorbid IQ [37]. In addition, all patients received symptom
measures rated using the Positive and Negative Syndrome Scale
(PANSS [38]) and the Comprehensive Assessment of At Risk
Mental States (CAARMS [34]) rating scales at baseline and at
clinical follow-up.
Clinical follow-up
Patients received a follow-up assessment at a median of 15.0
(interquartile range (IQR)= 11–23) months post baseline mea-
sures. Transition to a psychotic disorder was determined using the
structured clinical interview for diagnosis [35]. The percentage
change in CAARMS-positive symptom (unusual thought content,
bizarre ideas, perceptual abnormalities and disorganised speech)
severity rating from baseline to follow-up was calculated as
follows:
100 ´ ðsymptomratingatfollowup  symptomratingatbaselineÞ=
ðsymptomratingatbaselineÞ
where CAARMS scores were not available for patients (n= 3),
PANSS-positive severity ratings (after subtracting seven to correct
for the non-zero floor [39]) were used in their place to calculate
the percentage change in positive symptoms.
PET imaging acquisition and analysis
All participants received a PET scan to index dopamine synthesis
capacity at baseline. Subjects were asked not to eat or drink
(except water), and refrain from alcohol for 12 h prior to scan and
not to smoke for 2 h prior to the scan [40]. Imaging data were
obtained on a Siemens Biograph 6 HiRez PET scanner (Siemens,
Erlangen, Germany) in three-dimensional mode. To prevent
formation of radiolabelled metabolites that may cross the
blood–brain barrier, participants received 400 mg of entacapone,
a peripheral catechol-o-methyl-transferase inhibitor, and 150mg
of carbidopa, a peripheral aromatic acid decarboxylase inhibitor, 1
h before scan. Participants were positioned in the scanner with the
orbitomeatal line parallel to the transaxial plane of the tomograph.
Head position was marked and monitored, and a CT scan was
conducted for attenuation correction. Approximately 150 MBq of
18F-DOPA was administered by bolus intravenous injection 30 s
after the start of the dynamic PET scan. PET data were acquired in
32 frames of increasing duration, over the 95-min scan (frame
intervals: 8 × 15, 3 × 60, 5 × 120, 16 × 300 s). Our primary measure
was the whole striatal influx constant (Ki
cer, described as Ki in
some earlier publications [28]).
Image analysis was conducted blind to group status. A mutual
information algorithm was used to correct for head movement [41].
SPM8 was used to automatically normalise a tracer-specific 18F-
DOPA template [42], together with a striatal brain atlas using the
definition described by Martinez et al., which includes dividing the
striatum into three subdivisions based on the predominant origin of
projections to the striatum from limbic, associative and sensor-
imotor brain regions, respectively [43]. The whole striatum was our
primary region of interest. However, given recent findings that the
elevation in dopamine synthesis capacity in psychosis may be more
marked in the associative striatum [23], we conducted additional
exploratory analyses using the subdivisions for completeness.
Following visual inspection of the time-activity curves, Ki
cer was
calculated using the Patlak–Gjedde graphical approach adapted for
a reference tissue input function [44]. We have previously shown
this approach to have good reliability, with intraclass correlation
coefficients for the whole striatum of over 0.8 [45].
MRS acquisition
Scanning was conducted on a General Electric (Milwaukee,
Wisconsin, USA) Signa HDxt 3Tesla MRI scanner. Structural images
were acquired using a whole-brain three-dimensional sagittal T1-
weighted scan, with parameters based on the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) (TE= 2.85 ms; TR= 6.98 ms; inver-
sion time= 400ms; flip angle= 11°; voxel size 1.0 × 1.0 × 1.2 mm;
for full details see http://adni.loni.usc.edu/methods/mri-analysis/
mri-acquisition/). Structural T1 images were segmented into grey
matter, white matter and cerebrospinal fluid (CSF) using Statistical
Glutamatergic and dopaminergic function and the relationship to outcome. . .
OD Howes et al.
2
Neuropsychopharmacology (2019) 0:1 – 8
Parametric Mapping software (SPM8; Wellcome Trust Centre for
Neuroimaging, London, UK) to allow correction of the 1H-MRS
data for partial volume CSF contamination. 1H-MRS spectra
(PRESS–Point RESolved Spectroscopy; TE= 30ms; TR= 3000ms;
96 averages) were acquired in the left hippocampus (voxel
dimensions: 20 × 20 × 15mm (right–left, anterior–posterior,
superior–inferior); see Supplementary Fig. 1). We employed the
standard GE probe (proton brain examination) sequence, which
uses a standardised chemically selective suppression (CHESS)
water suppression routine. Unsuppressed water reference spectra
(16 averages) were also acquired as part of the standard
acquisition. Shimming and water suppression were optimised,
with auto-prescan performed twice before each scan.
LC-model 6.3-I0 [46] was used to estimate glutamate levels.
Following visual inspection of spectra quality, metabolite analyses
were restricted to spectra with linewidths at full-width at half-
maximum ≤0.1 ppm, Cramér–Rao lower bounds ≤20% and signal
to noise ratio ≥5. Model metabolites and concentrations used in
the basis set are fully detailed in the LC-Model manual (http://s-
provencher.com/lcmodel.shtml). An in-house script was used to
identify the relative distribution of white matter, grey matter and
cerebrospinal fluid in the voxel. Metabolite values were corrected
for the CSF content of the voxel using the formula Mcorr=M×
(WM+ 1.28 GM+ 1.55 CSF)/(WM+ GM), where M is the uncor-
rected metabolite value, and WM, GM and CSF are the white
matter, grey matter and cerebrospinal fluid fractions of the voxel,
respectively [47]. The 1H-MRS data are a sub-set of a larger sample
recently reported [48], but the PET and the integration of the PET
and 1H-MRS data have not been previously reported. The voxel
tissue content and imaging quality control variables are sum-
marised in Supplementary Table 9.
Statistical analysis
All statistical analyses were performed using R version 3.3.2 [49].
Significance was set at p < 0.05 (two tailed). Baseline clinico-
demographic variables were compared using independent t tests
or ANOVA for the continuous data, and the chi-square test for
categorical variables.
To test our first hypothesis that there was an inverse relation-
ship between glutamate and dopamine in the high-risk sample as
a whole, a linear regression analysis was performed with whole
striatal dopamine synthesis capacity as the dependent variable,
and glutamate concentrations as the predictor. We investigated
whether this relationship was altered following the addition of
potentially confounding variables (age, sex and ethnicity) to the
model, given possible effects of age [50], sex [51, 52] and ethnicity
[53], on the imaging measures.
To test our second hypothesis that dopamine synthesis capacity
at baseline predicted worsening of symptoms, we performed
linear regressions, analysing both the relationship between
dopamine synthesis capacity and percentage change in symp-
toms. Given possible effects of age [50], sex [51, 52] and ethnicity
[53], on the imaging measures, we conducted secondary
exploratory analyses that adjusted for these co-variates.
In addition, we conducted exploratory analyses to determine if
dopamine synthesis capacity predicted persistent functional
impairment. We also investigated whether baseline dopamine
levels were different from controls using independent t tests and
ANCOVA.
RESULTS
Fifty-one patients and 19 controls participated in the study. Forty-
seven patients received both PET and MRI scans (one received
only an MRI scan and three received only a PET scan), and all
controls received both PET and MRI scans. Time between scans
was similar for patients (median 17.7 weeks, IQR 13.4–33.3) and
controls (median 11.6 weeks, 4.3–23.3) (Mann–Whitney U Test,
p= 0.82). There were no significant differences between patient
and control groups in terms of age, gender, ethnicity or estimated
premorbid IQ (see Table 1). Of the 51 patients, 35 were followed-
up clinically, while 16 were lost to follow-up. There were no
significant differences in clinico-demographic variables between
the subjects with follow-up and those lost to follow-up (Table 2).
Imaging results in the total clinical high-risk sample relative to
controls
There were no significant differences between the total patient
and control groups in terms of dopamine synthesis capacity (t=
0.63, df= 67, p= 0.53) or hippocampal glutamate concentrations
(t= 0.57, df= 65, p= 0.52; see Fig. 1, Supplementary Fig. 2), and
this remained the case after controlling for the influence of age,
gender and ethnicity (group effect on dopamine synthesis
capacity: F= 0.39, df= 64, p= 0.54; and on glutamate concentra-
tions: F= 0.39, df= 62, p= 0.54). There were also no significant
differences in dopamine synthesis capacity between groups for
any of the striatal subdivisions (see Supplementary Information,
Supplementary Tables 1, 2).
Relationship between striatal dopamine synthesis capacity and
hippocampal glutamate levels
Figure 2 shows the relationship between hippocampal glutamate
concentrations and striatal dopamine synthesis capacity in
patients and controls. The bivariate regression showed that there
was no significant association between hippocampal glutamate
concentrations and striatal dopamine synthesis capacity in
patients (beta=−1.60 × 10−4, SE= 1.05 × 10−4, R2= 0.05, p=
0.13), including in the adjusted model (when age, gender and
ethnicity were added to the model (beta=−1.92 × 10−4, SE=
1.14 × 10−4, p= 0.10)), or in controls in either the bivariate
(beta=−1.01 × 10−4, SE= 2.40 × 10−4, R2= 0.01, p= 0.68) or
adjusted (beta= 5.92 × 10−4, SE= 2.85 × 10−4, p= 0.98) models.
No significant relationships were seen for any of the striatal
subdivisions either, in either patients or controls (see Supplemen-
tary Information, Supplementary Tables 5–8).
Table 1. Clinico-demographic details of study participants
Controls Patients P
n 19 51
Age 25.1(4.3) 23.0 (4.0) 0.06
% male 47 57 0.66a
% white ethnicity 79 73 0.81a
PANSS-positive n/a 14.6 (4.8) –
PANSS-negative n/a 12.9 (4.7) –
PANSS general n/a 31.5 (9.7) –
PANSS total n/a 59.1 (16.9) –
CAARMS-positive n/a 10.4 (4.4) –
CAARMS total n/a 42.3 (20.9) –
GAF 92.7 (5.7) 56.4 (9.6) <0.001
Premorbid IQ estimate 102.0 (12.7) 105.1 (13.7) 0.41
Hippocampal glutamate
concentration
8.06 (1.09) 8.27 (1.43) 0.57
Striatal Ki
cer 0.0128 (0.0011) 0.0126 (0.0010) 0.53
PANSS Positive and Negative Syndrome Scale, CAARMS comprehensive
assessment of the at-risk mental state, GAF general assessment of
functioning, IQ intelligence quotient estimated from national adult
reading test
Values are mean (SD). P- values refer to control–patient comparison. P-
values refer to t test unless otherwise indicated
aChi-square test
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Relationship between dopamine synthesis capacity and
subsequent worsening of symptoms
Dopamine synthesis capacity at baseline was associated with
subsequent worsening of psychotic (positive) symptoms (beta=
1.6 × 104, SE= 7.9 × 103, R2= 0.12, df= 32, p < 0.05) (see Fig. 3),
and this remained significant when age, gender and ethnicity
were added to the model (beta= 1.9 × 104, SE= 8.5 × 103, df= 29,
p < 0.05). The relationship was significant for the associative
subdivision, but not sensorimotor or limbic subdivisions (see
Supplementary Information, Supplementary Tables 3, 4). The
relationship was similar when the total symptom rather than the
positive symptom scores were examined, in both unadjusted
(beta= 4.5 × 104, SE= 1.8 × 104, df= 32, p < 0.05) and adjusted
models (beta= 4.8 × 104, SE= 2.0 × 104, df= 29, p < 0.05).
Transition to a psychotic disorder
Ten individuals (19.6% of the total high-risk sample) developed a
psychotic disorder during the follow-up period after the PET and
MRS scans. There was no significant difference in baseline
dopamine synthesis capacity between the transition (mean (SD):
0.0122 (0.001)) and non-transition (mean (SD): 0.0127 (0.001)) sub-
groups (t= 1.3, df= 48, p= 0.28).
DISCUSSION
Our first main finding is that in people at clinical high risk for
psychosis, striatal dopamine synthesis capacity predicted the
worsening of psychotic symptoms. This adds to evidence that
dopamine synthesis and release capacity are positively correlated
with psychotic symptom severity [54–56], and treatment response
[57] in patients with a psychotic disorder. Although the relation-
Table 2. Clinico-demographic details of patients with and without
clinical follow-up
Sample with
follow-up
Lost to follow-
up
P
n 35 16
Age 23.1 (3.9) 22.7 (4.5) 0.75
% male 60 50 0.72a
% white ethnicity 71 75 0.99a
PANSS-positive 14.1 (4.4) 15.8 (5.5) 0.25
PANSS-negative 12.2 (4.5) 12.3 (5.2) 0.52
PANSS general 31.9 (9.9) 30.7 (9.5) 0.70
PANSS total 59.3 (16.3) 58.7 (18.8) 0.91
CAARMS-positive 10.8 (4.4) 9.36 (4.31) 0.30
CAARMS total 43.4 (20.9) 42.4 (23.1) 0.89
GAF 55.0 (9.5) 59.4 (9.6) 0.14
Premorbid IQ estimate 107.0 (10.7) 101.1 (18.2) 0.16
Hippocampal glutamate
concentration
8.26 (1.5) 8.29 (1.4) 0.95
Striatal Ki
cer 0.0127 (0.001) 0.0125 (0.001) 0.50
PANSS Positive and Negative Syndrome Scale, CAARMS comprehensive
assessment of the at-risk mental state, GAF general assessment of
functioning, IQ intelligence quotient estimated from national adult
reading test
Values are mean (SD) or % in case of sex and ethnicity. P-values refer to t
test unless otherwise indicated
aChi-square test
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Fig. 1 Mean (SD) striatal dopamine synthesis capacity and hippocampal glutamate concentrations are not significantly different between
patients and controls (p= 0.55 and p= 0.52, respectively)
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ship was strongest for the associative subdivision, specificity to
this region remains to be established given the high degree of
collinearity between dopamine measures for all three subdivisions
and that we did not test for an interaction. However, there was no
significant difference between patients who later developed a
psychotic disorder relative to those who did not, contrary to our
previous findings [32]. This could be due to the fact that the
difference between receiving a diagnosis of a psychotic disorder
or not can come down to small differences in duration or severity
of symptoms, for example, the difference between 7 days versus
6 days of psychotic symptoms [34]. It has been argued that these
differences are unlikely to be clinically meaningful, and that a
dimensional approach to psychosis may be more appropriate [58].
This is also consistent with evidence that there is a dimensional
relationship between dopamine dysregulation and the induction
of psychotic symptoms in healthy volunteers as well [59–61].
Factors other than symptom levels may also influence the
diagnostic process, such as the patient’s coping skills and level
of functioning. It should also be noted that some patients in the
non-transition group showed a greater worsening of symptoms
than patients in the transition group (see Supplementary Fig. 3),
and that some individuals develop a psychotic disorder up to 10
years after [62], indicating that further follow-up is required to
determine if there are any transitions in the non-transition group.
Notwithstanding this, taken together, our findings that there was a
relationship between dopaminergic dysfunction and worsening of
symptoms, but not transition to psychosis, indicate that dopamine
dysfunction is more strongly linked to the development of
symptoms than a diagnosis of a psychotic disorder. These findings
add to other evidence that alterations in subcortical dopamine
function in subjects with mental health problems may be more
related to psychotic symptoms than to diagnostic categories
per se [26, 54]. For example, patients with psychotic bipolar
disorder show a similar elevation of striatal dopamine synthesis
capacity to patients with a schizophreniform psychosis [54].
Our finding that there was no significant relationship between
hippocampal glutamate levels and striatal dopamine synthesis
capacity contrasts with our previous finding in subjects at clinical
high risk of psychosis, which found a negative relationship with r=
0.54 [21]. It is possible that our failure to detect a relationship in
the current study is due to a type II error. However, the patient
sample in this study (n= 51) was much larger than in the previous
study (n= 14), and had >80% power to detect the anticipated
moderate or larger (r > 0.4) relationship between dopamine and
glutamate indices. Thus, our study was well powered to detect the
anticipated effect size, although it is possible that there is a
smaller effect. It should be recognised that the MRS glutamate
signal at 3 T is a composite of intra and extrasynaptic glutamate,
and glutamine [3, 63]. Thus, we cannot exclude the possibility that
alterations in synaptic glutamate levels are masked by other
components of the signal, or indeed, that there are alterations in
glutamate receptor levels. Notwithstanding these caveats, our
findings are not consistent with the model that increased
hippocampal glutamate levels dysregulates striatal dopamine
function. They do not, however, rule out the alternative hypothesis
suggested by preclinical models and clinical findings of hippo-
campal overactivity in psychosis [8, 12, 13, 18–20], that it is
disinhibition of glutamate output neurons, and not altered
glutamate drive in the hippocampus, that leads to subcortical
dopaminergic dysregulation. This disinhibition could occur
secondary to reduced GABAergic interneuron function, or other
mechanisms affecting glutamatergic neuronal excitability that
occur without concomitant measurable differences in glutamate
concentrations in the hippocampus. In this case, one would not
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Fig. 2 Hippocampal glutamate concentration is not significantly related to striatal dopamine synthesis capacity in patients (red; p= 0.13) or
controls (blue, p= 0.68)
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predict a relationship between hippocampal glutamate levels and
striatal dopaminergic function, as it would be glutamate levels at
the site of the projections’ termination (i.e., the striatum) that
would show an association with dopamine function. A recent
study has reported an inverse relationship between glutamate
concentration in the anterior cingulate cortex and striatal
dopamine synthesis capacity in patients with first-episode
psychosis [64], and this has been seen also in healthy controls
along with a direct association between striatal glutmate levels
and striatal dopamine synthesis capacity [65]. Unfortunately, we
did not measure glutamate concentration in the striatum or
anterior cingulate cortex in this study. Further studies are
warranted to test the relationship between striatal dopamine
function and glutamate concentration in other brain regions in
high-risk subjects.
However, an alternative hypothesis is that it is disinhibition of
hippocampal glutamatergic output neurons, as opposed to
glutamatergic drive in the hippocampus, that leads to striatal
dopaminergic dysregulation [8],
We did not find a difference in striatal dopaminergic function
between clinical high-risk subjects overall and controls, in contrast
to previous findings [28, 29, 66]. This difference could reflect
changes in the population referred to early detection services over
time, with evidence indicating that subjects are referred earlier in
the at risk period in more recent cohorts compared with earlier
cohorts [67]. This is consistent with the transition rate in the
present sample, which was ~19%, compared with ~35% in earlier
samples [28, 32]. Transition rates similar to those in our current
sample have also been reported in more recent cohorts from
clinical studies around the world [2, 62], indicating that our current
sample is likely to be representative of subjects currently referred
to at risk services. Nevertheless, the lower transition rate and
evidence that there may be transitions up to 10 years after
presentation [62], indicates that the current finding of no
difference in dopamine synthesis capacity should be considered
as preliminary pending long-term follow-up of our current sample.
The potential lack of generalisability to cohorts, where transition
rates are greater, is a limitation that pertains to all the negative
findings reported. We also did not detect a significant difference
in hippocampal glutamatergic function between the high-risk
subjects and controls, in contrast to our previous findings in a
larger study that included the current cohort [48], although in
agreement with previous studies in smaller samples that also did
not detect significant differences [21, 68]. Thus, the difference
between the Bossong et al. finding [48] and our current results
may reflect the lower power in the current sample.
Methodological considerations
A number of subjects were lost to follow-up, which could
introduce bias into the outcomes. However, the clinical and
demographic characteristics of these subjects were not signifi-
cantly different from those in the other groups, indicating this
unlikely to be a major bias. It should be recognised that some non-
transition subjects might subsequently develop a psychotic
disorder. However, as the peak period for transition to psychosis
is within the first year of follow-up [2], it is likely that we have
identified the majority of transitions. Although it was not
significant, there was a trend for the controls to be older than
the patients. However, including age as a covariate in analyses did
not have a major effect on findings.
Implications
Our finding that dopamine synthesis capacity predicted the
worsening of psychotic symptoms but was not linked to transition
suggests that other factors are involved in the diagnosis of
psychotic disorder. One interpretation could be that dopamine
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Fig. 3 Striatal dopamine synthesis capacity at baseline is directly associated with subsequent increase (worsening) of psychotic (positive)
symptoms (r= 0.35, p < 0.05) in people at clinical risk of psychosis
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dysfunction underlies the development of psychotic symptoms,
but whether these have a functional impact depends on
additional factors, such as the coping skills, and psychological
response of the individual, and their social support, consistent
with psychosocio-biological models of psychosis [69–71]. Another
possibility is that in the at-risk period, small differences in
dopamine drive short-term psychotic-like experiences, but
whether these become long-lasting and more severe depends
on the development of further dopamine dysregulation. These
possibilities are not mutually exclusive and a combination of both
is possible [69].
Our finding that hippocampal glutamate is not linked to striatal
dopamine dysfunction does not support the hypothesis that
elevated hippocampal glutamatergic drive is driving striatal
dopamine dysfunction, but is consistent with models that
disinhibition of glutamatergic projections could drive striatal
dopamine dysregulation. This predicts increased glutamate levels
in targets of glutamatergic projections from the hippocampus,
including the striatum. Elevated glutamate levels have been
reported in the striatum in people at risk of psychosis, and linked
to the transition to psychosis [72, 73]. Unfortunately, we did not
measure striatal glutamate levels due to time constraints. New
methods to index inhibitory regulation of hippocampal projection
neurons, and MRS studies involving the targets of hippocampal
projection neurons, are needed to test this further.
CONCLUSIONS
Striatal dopamine synthesis capacity predicts worsening of
psychotic-like symptoms, but is not strongly related to transition
to psychosis or hippocampal glutamate levels, indicating a role for
dopamine in the development of symptoms but that other factors
contribute to the transition to a psychotic disorder.
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